ArticleJournal for immunotherapy of cancer2026
IFN-γ PET imaging stratifies and predicts response to CD137 agonism in a syngeneic colorectal tumor model.
Article in Journal for immunotherapy of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe secretion of interferon-γ (IFN-γ) by activated immune cells is one of the hallmarks of response to cancer immunotherapy. Hence, detection of this cytokine via imaging can help determine an activated antitumor immune response. We have previously shown that positron emission tomography (PET) imaging of IFN-γ using [
methodsBiolayer interferometry and neutralization assays were performed. [
resultsThe affinity of the DFO-anti-IFN-γ for IFN-γ remained similar to the unconjugated anti-IFN-γ. Binding did not perturb the signaling function of the cytokine. The uptake of [
conclusionDelineating IFN-γ through PET imaging stratified tumor response at the early stages of CD137 agonism prior to tumor morphological changes. Thus, IFN-γ PET holds promise as a predictive biomarker of response to immunotherapy. STATEMENT OF SIGNIFICANCE: IFN-γ PET imaging is predictive of response to immunotherapy, potentially bridging an unmet clinical need for early detection of antitumor immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.